The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque

Newsletter

Get the latest science from Atuka

Sign up to receive our quarterly newsletter featuring the latest developments in Parkinson’s disease research.

List Signup

Talk to our experts

Advance your therapeutic program